Waystar Holding (WAY) has put its AI ambitions front and center, rolling out new AltitudeAI capabilities that target healthcare revenue cycle automation, silent denials, revenue leakage, and personalized patient billing, supported by an expanded Google Cloud collaboration.

Despite the recent AltitudeAI launch and conference activity, Waystar Holding’s 1-month share price return of 7.54% comes alongside a year-to-date share price return of 19.57% and a 1-year total shareholder return of 32.12%, suggesting sentiment has been improving in the very short term after a tougher stretch.

If you are interested in how AI is reshaping healthcare beyond Waystar, this is a good moment to size up other opportunities using our screener for 32 healthcare AI stocks

Waystar now trades about 44% below one intrinsic value estimate, with a roughly 43% discount to the average analyst price target. However, recent returns have been weak, raising the question of whether this is a reset that opens a buying window or if the market is already discounting future growth.

Most Popular Narrative: 30.1% Undervalued

Waystar Holding's most followed narrative points to a fair value of about $36.09 per share versus the last close of $25.23, putting a clear spotlight on growth and cash flow assumptions that sit well above what the current share price reflects.

The acquisition of Iodine Software, a leading provider of AI-powered clinical intelligence, will expand Waystar's total addressable market by over 15%, accelerate its product roadmap, and immediately boost gross margins and adjusted EBITDA margins, setting up compounding, long-term revenue and earnings growth.

Curious how this story gets to a higher fair value than today's price? The narrative leans on faster revenue expansion, rising margins, and a richer future earnings multiple, all tied to specific forecasts and timelines that are only visible once you see the full set of assumptions.

Result: Fair Value of $36.09 (UNDERVALUED)

However, there are still pressure points to watch, including higher leverage from the US$1.25b Iodine deal and potential pricing pressure as large health systems consolidate.

Another Angle: Multiples Point To A Richer Price

While the narrative and intrinsic models frame Waystar as 30.1% undervalued, the current P/E of 43.2x is well above both the estimated fair ratio of 26.4x and peer or industry levels around the high 20s. This lifts valuation risk and raises the question of how much optimism is already reflected in the price.

To see how that premium compares with peers and what the fair ratio implies for potential re rating, take a closer look at the full valuation breakdown, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between upside potential and valuation risk, this is a good time to move quickly, test the numbers for yourself, and then weigh those positives by reviewing 4 key rewards

Ready to hunt for your next idea?

If you stop with just one stock, you could miss other setups that better fit your goals, so put a few more ideas on your radar today.

• Target potential mispricings by scanning companies that look undervalued on quality and fundamentals with the 53 high quality undervalued stocks.
• Prioritize resilience by checking out companies that pair sturdy balance sheets with solid fundamentals using the solid balance sheet and fundamentals stocks screener (44 results).
• Spot potential early stage standouts before they are widely followed through the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.